After Decades of Stagnation, a Pill Doubles Survival for Pancreatic Cancer — But Questions Remain

Pancreatic cancer kills roughly 470,000 people per year worldwide and has a five-year survival rate of about 6% in Europe and the United States [1]. For nearly three decades, treatment advances have been measured in weeks, not months. On May 31, 2026, results from a global phase 3 trial presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago showed that a once-daily oral pill called daraxonrasib nearly doubled median overall survival in previously treated metastatic pancreatic cancer — prompting a standing ovation at the plenary session and immediate comparisons to the biggest advance the field has seen since FOLFIRINOX in 2011 [2][3].

The results were simultaneously published in the New England Journal of Medicine [4]. But as the oncology community processes the data, independent analysts are raising pointed questions about toxicity, long-term durability, pricing, and whether the framing of this as the "biggest breakthrough in 50 years" can withstand scrutiny.

The Numbers: What the Trial Actually Showed

The RASolute 302 trial enrolled 500 patients with metastatic pancreatic ductal adenocarcinoma (PDAC) across 59 sites in six countries — spanning North America, Europe, and Asia [5]. All participants had progressed on one prior line of chemotherapy, either fluoropyrimidine- or gemcitabine-based. They were randomized to receive either oral daraxonrasib or investigator's choice of standard-of-care chemotherapy.

The headline results [2][3][5]:

• Median overall survival: 13.2 months (daraxonrasib) vs. 6.7 months (chemotherapy) — a hazard ratio of 0.40, meaning a 60% reduction in the risk of death (p < 0.0001)
• Median progression-free survival: 7.3 months vs. 3.5 months
• Objective response rate: 31.6% vs. 11.2%

These figures are striking in context. In the second-line setting — where RASolute 302 was conducted — no previous therapy had demonstrated median overall survival beyond approximately 6-7 months [6].

Source: NEJM, JCO (compiled)

Data as of Jun 1, 2026CSV

How It Works: Cracking the "Undruggable" Target

KRAS mutations were identified in the early 1980s as a primary driver of pancreatic cancer, present in roughly 90% of PDAC tumors. For decades, KRAS was considered "undruggable" — the protein's smooth surface offered no obvious binding pocket for small molecules [7]. The first KRAS-targeting drug, sotorasib, won FDA approval in 2021 for lung cancer with a specific KRAS G12C mutation, but that particular mutation is rare in pancreatic cancer [7].

Daraxonrasib represents a different approach. Developed by Revolution Medicines (Nasdaq: RVMD), it is an oral "multi-selective RAS(ON) inhibitor" — meaning it binds to multiple variants of the RAS protein in its active ("on") state, rather than targeting a single mutation. It functions as a "molecular glue" alongside cyclophilin A to block RAS protein signaling that drives uncontrolled cell growth [5][8].

This broad mechanism matters. Unlike mutation-specific inhibitors such as sotorasib, daraxonrasib showed activity across the RAS G12 population and the broader intent-to-treat population regardless of specific RAS mutation subtype. Brian Wolpin, M.D., the trial's principal investigator and director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, stated: "Given its ability to inhibit mutant and non-mutant RAS(ON) proteins, daraxonrasib has broad relevance to all metastatic pancreatic cancer patients" [5].

Because approximately 90% of pancreatic cancers harbor RAS mutations, the potential eligible population is large — a significant share of the roughly 510,000 people diagnosed with pancreatic cancer globally each year [1][5].

Placing This in Historical Context

To understand why the oncology community reacted as it did, consider the trajectory of pancreatic cancer treatment:

• 1997: Gemcitabine became the standard of care with a median OS of 5.7 months [9]
• 2005: Adding erlotinib to gemcitabine provided a marginal gain to 6.2 months [9]
• 2011: FOLFIRINOX, a four-drug chemotherapy combination, raised median OS to 11.1 months — but only in fit patients with good performance status, and with considerable toxicity [9][10]
• 2013: Gemcitabine plus nab-paclitaxel offered 8.5 months median OS as a more tolerable alternative [9]

No treatment in the second-line setting (after initial chemotherapy fails) had previously achieved median OS beyond roughly 6-7 months. Daraxonrasib's 13.2 months in the second-line setting exceeds even FOLFIRINOX's first-line result from 2011, which was restricted to patients who had not yet received any chemotherapy [2][10].

Chris Chen, an oncologist who was not an investigator on the trial, called the results "truly an earth-shattering moment in pancreatic cancer." Matthew Katz noted that for this patient population, "six months is huge. It is a definite win" [7].

The Toxicity Question

The safety data tell a more complex story than the survival headlines suggest.

Common adverse events in the daraxonrasib arm included rash (88%), diarrhea (63%), stomatitis/mucositis (63%), nausea (53%), vomiting (50%), and fatigue (35%) [11]. Grade 3 or higher adverse events occurred in 43.6% of the daraxonrasib group, compared with 57.5% in the chemotherapy group. The most frequent severe toxicities were rash (14%) and stomatitis (12%) [11].

On the surface, daraxonrasib appears more tolerable than chemotherapy: treatment-related serious adverse events occurred in 10.8% of patients receiving daraxonrasib versus 18.7% on chemotherapy. Discontinuation due to adverse events was remarkably low at 1.2% for daraxonrasib vs. 11.2% for chemotherapy [11].

However, Dr. Timothée Olivier, a Swiss oncologist who publishes independent trial analyses, raised concerns about how safety data were presented. He noted that prior press releases characterized the drug's safety profile as "manageable" while distributing Grade 3+ adverse events across multiple categories — a framing that could obscure the overall toxicity burden [12]. Dose modifications due to adverse events were required in 70% of patients receiving daraxonrasib [11].

One treatment-related death (Grade 5 pneumonitis) occurred in the daraxonrasib arm (0.4%), while none occurred in the chemotherapy arm [11]. Former U.S. Senator Ben Sasse, who participated in the trial, publicly described the drug as "nasty," reporting an inability to grow skin and spontaneous bleeding — a characterization at odds with the trial's tolerability framing [12].

Peer Review and Methodological Scrutiny

The trial's credibility is strengthened by simultaneous publication in the New England Journal of Medicine — the field's most prestigious journal — alongside the ASCO plenary presentation [4]. This is a higher evidentiary bar than a conference abstract or press release alone.

The trial design has drawn praise: a biomarker-selected, randomized phase 3 trial with overall survival as the primary endpoint — not a surrogate like progression-free survival — against active chemotherapy in a difficult-to-treat population [12].

But independent statisticians have raised methodological questions. Olivier flagged that the headline OS result (HR 0.40 in the intent-to-treat population) was technically a secondary endpoint, while the primary endpoint in the KRAS G12 mutant subgroup had not been fully reported at the time of the presentation [12]. He also raised the concern that early stopping rules, if applied, can inflate effect estimates, and that early separation in survival curves often attenuates with longer follow-up — a pattern observed in prior pancreatic cancer trials like NAPOLI-1 [12].

The trial was open-label (not blinded), meaning both patients and physicians knew which treatment they were receiving. While common in oncology trials comparing oral drugs to IV chemotherapy, open-label designs can introduce bias in subjective endpoints like quality of life.

Source: OpenAlex

Data as of Jan 1, 2026CSV

Who Funded This, and Who Benefits Financially?

RASolute 302 was sponsored by Revolution Medicines, a publicly traded biopharmaceutical company headquartered in Redwood City, California. The company secured a $2 billion funding agreement with Royalty Pharma to support global development and commercialization of its RAS inhibitor portfolio [13]. Revolution Medicines' operating expenses are projected at $1.6-1.7 billion in 2026, reflecting the scale of its commercialization push [14].

The lead investigators — including Eileen M. O'Reilly (Memorial Sloan Kettering), Zev A. Wainberg (UCLA), Andrew E. Hendifar (Cedars-Sinai), and Wolpin (Dana-Farber) — are affiliated with major academic cancer centers [4][5]. Financial disclosures are included in the NEJM publication, as required by journal policy, though the full details of individual investigator relationships with Revolution Medicines were not available in the public summaries reviewed for this article.

Dr. Shubham Pant, a professor of GI Medical Oncology at MD Anderson Cancer Center and a trial investigator, has been prominently quoted describing the results as "completely changing — transforming — the care of these patients" [8]. Pant's specific financial relationships with Revolution Medicines were not independently verified.

The Path to Approval — and the Access Problem

The FDA has already taken several favorable steps toward daraxonrasib:

• Breakthrough therapy designation granted in 2025 [14]
• Orphan drug designation for pancreatic cancer [14]
• National Priority Voucher under the FDA Commissioner's pilot program [14]
• Expanded access program authorized on May 1, 2026, with Revolution Medicines already shipping the drug to physicians [15]

Revolution Medicines CEO Mark Goldsmith stated the company "will file soon for FDA approval," though no specific timeline has been disclosed [15]. Given the magnitude of the survival benefit and the FDA's expedited pathways, approval could come within 6-12 months of filing.

The cost question looms large. The company has not announced pricing. For context, sotorasib (Lumakras), the first KRAS inhibitor approved for lung cancer in 2021, launched at approximately $17,900 per month — roughly $215,000 per year [16]. Given Revolution Medicines' $2 billion commercialization investment and the drug's orphan designation (which provides market exclusivity), analysts expect daraxonrasib to be priced in a comparable or higher range.

Access in low- and middle-income countries (LMICs) — where pancreatic cancer incidence is rising fastest — remains unaddressed. The company has not announced any global access partnerships, tiered pricing, or licensing agreements with generic manufacturers. Given that approximately 80% of pancreatic cancer deaths occur outside high-income countries [1], this gap is significant.

Why This Time Might Be Different — and Why It Might Not

Pancreatic cancer has a long history of promising trial results that failed to change population-level survival curves. The 2011 FOLFIRINOX trial improved median survival by 4.3 months in the first-line setting, yet the five-year survival rate for the disease has barely moved from 6% to approximately 13% over the past two decades [9][10].

Several features of the RASolute 302 trial distinguish it from prior false dawns:

1. Targeting the driver mutation: Unlike previous chemotherapy improvements, daraxonrasib addresses the dominant oncogenic driver (KRAS) present in ~90% of pancreatic tumors — a biologically rational approach rather than an empiric combination of cytotoxic drugs [5][7].

2. Magnitude of effect: A hazard ratio of 0.40 (60% risk reduction) is unusually large for a solid tumor trial. Most oncology breakthroughs produce hazard ratios of 0.60-0.75 [2][3].

3. Oral administration: As a once-daily pill, daraxonrasib avoids the burden of IV infusions, potentially improving adherence and quality of life — though formal quality-of-life data from RASolute 302 have not yet been published [5][7].

4. Broad applicability: Activity across multiple RAS mutations, not just a rare subtype, means the drug could benefit the majority of pancreatic cancer patients [5].

For this result to translate into real population-level gains, several conditions would need to hold: the survival benefit would need to be durable with longer follow-up; the drug would need to receive regulatory approval and achieve broad uptake; and pricing would need to permit access beyond wealthy health systems.

What Comes Next

Revolution Medicines is already running RASolute 303, a trial evaluating daraxonrasib in the first-line setting — combined with chemotherapy for newly diagnosed metastatic pancreatic cancer [5]. If daraxonrasib shows similar benefit earlier in the disease course, the impact could be substantially larger.

An mRNA-based pancreatic cancer vaccine developed by Memorial Sloan Kettering and BioNTech is also in early trials, showing durable immune responses in a subset of patients [17]. The convergence of targeted therapy and immunotherapy approaches represents the most intensive period of pancreatic cancer research in the disease's history.

Whether daraxonrasib's trial results will translate into the kind of population-level survival shift that has occurred in lung cancer, melanoma, and certain leukemias over the past 15 years remains the central unanswered question. The data from RASolute 302 are the strongest evidence yet that such a shift may be possible in pancreatic cancer. They are not, however, proof that it has arrived.